![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects](https://www.mdpi.com/vaccines/vaccines-10-01223/article_deploy/html/images/vaccines-10-01223-g001.png)
Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland | The University of Edinburgh Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland | The University of Edinburgh](https://www.ed.ac.uk/sites/default/files/styles/landscape_breakpoints_theme_uoe_mobile_1x/public/thumbnails/image/v.6_omicron.png?itok=ZFbrm-WP)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland | The University of Edinburgh
Eric Topol on X: "First data on booster vaccine effectiveness vs Omicron (581 cases): drop in protection vs symptomatic infection by 2 doses (AZ ->0, Pfizer-> <40%) restored to ~75% with 3rd
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog](https://i0.wp.com/covidblog.oregon.gov/wp-content/uploads/2022/09/bivalent.jpg?fit=4431%2C2954&ssl=1)
Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog
Eric Topol on X: "The decline of vaccine effectiveness vs Omicron. Simplified (no 95% CI) summary for Pfizer vaccine vs Delta, + booster, and vs Omicron, + booster (early @UKHSA data) vs
![Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33169-0/MediaObjects/41467_2022_33169_Fig1_HTML.png)
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
![FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN](https://media.cnn.com/api/v1/images/stellar/prod/230109124641-moderna-bivalent-vaccine.jpg?c=original)